ClinicalTrials.gg
Active, not recruitingNCT06917404Updated Sep 1, 2026

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

A Phase 3 interventional study of Pentosan Polysulfate Sodium twice weekly and Placebo in Osteoarthritis, Knee, sponsored by Paradigm Biopharmaceuticals Ltd.. Active, not recruiting at 57 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Paradigm Biopharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
62nd of 691
466 · median 72
Started
2025
with 36 others
Phase 3
76 of 796
6 open now
Primary completion
2027-07
later than 83 of 151 live
Registered
748th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 62nd largest by planned enrollment of the 691 interventional ones that give a count, is one of 37 that started in 2025, is one of 76 in phase 3, reaches primary completion later than 83 of the 151 other live ones, and was the 748th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.

Study details include:

  • The study duration will be up to 64 weeks.
  • The treatment duration will be 6 weeks.
  • The visit frequency will be twice weekly during treatment.
  • The visit/contact frequency will be every 4-6 weeks during the 52-week Follow-up period.
  • Approximately 466 participants will be enrolled into this study.
Read the detailed description

This is a randomised, double-blind, placebo-controlled, multicenter study that will evaluate the dose and treatment effect of PPS in participants with knee OA pain.

Participants will be randomised 1:1 to receive twice-weekly subcutaneous (SC) injections of 2 mg/kg PPS or placebo for 6 weeks.

An interim analysis for a potential early conclusion is planned after approximately 50% of participants complete Day 112.

The primary analysis will be conducted when all participants complete Day 112. A final analysis will be conducted when the last participant reaches Day 404.

The maximum duration for each participant is up to 64 weeks, which includes

  • 7-week Screening Period from Day -45 to Day -1
  • 6-week Treatment Period from Day 1 to Day 39
  • 52-week Follow-up Period from Day 40 to Day 404
03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • osteoarthritis
  • knee
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥18 years of age inclusive, at the time of signing the .
  2. Clinical diagnosis of OA in the index knee by American College of Rheumatology 1986 criteria.
  3. Radiographic diagnosis (confirmed by radiologist) of knee OA classified K-L grade 2, 3, or 4 on standing anterior-posterior X-ray of the index knee.
  4. Participant is unresponsive for at least 6 months preceding Screening to any two combinations of OA therapies (one from each A and B) within the last 12 months that include: A.) conservative non-pharmacologic therapy (exercise, weight loss, physical therapy) or simple analgesics (e.g., acetaminophen) and B.) pharmacological treatment (topical or oral NSAIDs [or cyclooxygenase (COX) inhibitor], or intra-articular [IA] injections), or participant is unable to take NSAIDs because of or inability to tolerate.
  5. Average daily pain (ADP) numerical rating scale (NRS) score of 4-9 in the index knee at Screening.
  6. Baseline average weekly ADP NRS score of 4-9 in the index knee in the 7 days prior to randomization.
  7. No more than one 24-hr average pain score (0-10 NRS) reported as "10" during the 7 days prior to Day 1.
  8. of ≥18.0 to ≤39.0 kg/m2.
  9. Female subjects of and Male subjects must agree to comply with protocol specified requirements
  10. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  11. Completion of at least 11 out of 14 ADP NRS scores for at least 14 days prior to randomisation.
  12. Current non-pharmacologic treatment regimen for knee OA (excluding knee brace) must be stable for at least 2 weeks before Day 1 and remain stable throughout the study. Participant must be willing to abstain from starting a new or changing their non-pharmacologic treatment regimen for the duration of the study.
  13. Willing to stop treatment with oral and topical NSAIDs, and all other systemic pain medications (except allowed rescue medication) from 2 weeks before Day 1 to end of study.
  14. Agrees to use acetaminophen/paracetamol or topical analgesics (topical NSAIDs are prohibited) as rescue therapy if required.

Exclusion criteria

Exclusion Criteria:

  1. History of idiopathic or immune-mediated thrombocytopenia including history of HIT with or without thrombosis.
  2. History of major bleeding disorders including haemophilia.
  3. Currently active or recent history (within preceding 12 months) of a gastric or duodenal ulcer, or suspicion of gastrointestinal tract bleeding.
  4. Recent cerebral bleeding or operation on brain, spine, or eyes within 12 months of Day 1.
  5. Spinal anaesthesia within 14 days of Day 1.
  6. Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy, or other moderate to severe pain disorder that may confound assessments or self-evaluation of the pain associated with osteoarthritis. Participants with a present (current) history of sciatica are not eligible for participation. Participants with a history of sciatica who have been asymptomatic for ≥3 months and who have no evidence of radiculopathy or sciatic neuropathy on thorough neurologic examination are eligible for participation.
  7. History of other disease that may involve the index knee, including inflammatory joint disease such as rheumatoid arthritis (RA), seronegative spondyloarthropathy (e.g., ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease-related arthropathy), crystalline disease (e.g., gout), endocrinopathies, metabolic joint diseases, lupus erythematosus, joint infections, Paget's disease, or tumours.
  8. History of to PPS, heparin or heparin-like drugs, or drugs of a similar chemical or pharmacological class.
  9. Predisposition to hypersensitivity due to multiple (2 or more) atopic diseases (such as atopic eczema, asthma, and chronic allergic rhinitis and/or rhinoconjunctivitis) or multiple (2 or more) severe allergies.
  10. Allergy or to tetracosactide (Synacthen®), cosyntropin (Cortrosyn®).
  11. Allergy or contraindication to gadolinium.
  12. Chronic medical conditions including but not limited to those stated below requiring medical regime changes within 60 days before Day 1.

    Concurrent unstable peripheral, cardiac, and cerebral vascular disease, poorly controlled and asthma, coagulopathies, uncontrolled neurological conditions, active tuberculosis, active infections, symptomatic cardiac arrhythmias, adrenal insufficiency (primary or central), nephrotic syndrome, cirrhosis ( stage B or C), Gilbert syndrome, uncontrolled diabetes, and uncontrolled hypothyroidism or hyperthyroidism, or mental or emotional disorders that preclude reliable study participation.

  13. History of pituitary irradiation or recent (within 1 year) history of transsphenoidal surgery.
  14. Any cancer within the previous 5 years, except for basal cell carcinomas.
  15. History or current polyglandular syndromes.
  16. Presence of any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per the protocol.
  17. Current treatment with anticoagulants or antiplatelet drugs within 2 weeks before Day 1, excluding aspirin ≤150 mg/day.
  18. Previous treatment with PPS in any form.
  19. Current or recent (within 90 days before Day 1) or immunomodulatory (with immunosuppressive effects) systemic therapy including but not limited to oral, inhaled, intranasal, intra-articular (IA) and topical (occasional use of topical, inhaled or intranasal corticosteroids is acceptable).
  20. Use of NSAIDs with 2 weeks before Day 1.
  21. Use of opioids within 6 weeks before Day 1.
  22. Use of glucosamine or chondroitin within 6 weeks before Day 1.
  23. Use of bisphosphonates and denosumab within 12 weeks before Day 1.
  24. Use of iloprost within 12 weeks before Day 1.
  25. Use of a knee brace on the index knee within 2 weeks before Day 1.
  26. Systemic steroids administered intravenously, intramuscularly, or orally for OA or other indications within 8 weeks before Day 1.
  27. Intra-articular (IA) injections to the index knee: steroids within 12 weeks before Day 1; hyaluronic acid (HA) or any other IA injections within 24 weeks before Day 1.
  28. Stem cells or -rich plasma within 12 months of Day 1.
  29. Cannabinoids within 30 days before Day 1.
  30. Use of individual vitamins and dietary supplements known to alter haemostasis within 2 weeks before Day 1, including ajoene, birch bark, cayenne, Chinese black tree fungus, cumin, evening primrose oil, feverfew, garlic, ginger, ginkgo biloba, ginseng, grapeseed extract, milk thistle, omega 3 fatty acids, onion extract, St. John's wort, turmeric, vitamins C and E, vitamin K, (multivitamins allowed).
  31. Known exposure to heparin within the last 100 days as determined by history of drug use or history of the following medical conditions or interventions: cardiac bypass surgery or thromboembolic disease.
  32. Treatment with dehydroepiandrosterone sulfates (DHEA-S) within 6 weeks before Day 1.
  33. Chronic use of oral glucocorticoid receptor antagonists or cortisol synthesis inhibitors within 12 weeks before Day 1.
  34. Biotin within 72 hours before Screening.
  35. Megestrol acetate within 6 weeks before Day 1.
  36. Participation in another clinical trial or administration of any IP or experimental product within 24 weeks or 5 half-lives (whichever is longer) before Day 1.
  37. [aPTT]) > 36 seconds, platelets \<150,000/μL, or liver enzyme tests ( [AST] or alanine aminotransferase [ALT]) ≥ 2 × at Screening.
  38. Total ≥1.5 ULN.
  39. Active or chronic virus, virus, or uncontrolled infection (detectable virus or diagnosis of AIDS); participants with HIV infection must be on chronic suppressive antiviral medication.
  40. Evidence of any of the following conditions in any screening imaging: excessive malalignment (≥10 degrees varus or valgus) of the knee, subchondral insufficiency fracture (SIF), osteonecrosis/bone infarct, osteochondritis dissecans, stress or acute fracture, atrophic OA, pathologic fracture, primary or tumour, infectious arthritis or osteomyelitis, chronic or acute, Charcot's knee joint, synovial chondromatosis, certain posterior root tears of the meniscus, bone contusion, bone marrow oedema syndrome, bone marrow infiltration, gout, severe chondrocalcinosis, other arthropathies (e.g., RA, psoriatic arthritis), systemic metabolic bone disease (e.g., Paget's disease, metastatic calcifications) or other conditions identified by a radiologist or Medical Monitor which may interfere with a participant's assessment of pain.
  41. Any abnormalities on clinical chemistry, haematology, urinalysis, physical examination, medical history, or vital signs as judged by the Investigator (at Screening).
  42. Resting, supine blood pressure (BP) ≥160 mmHg in systolic pressure or ≥100 mmHg in diastolic pressure at Screening. If a participant is found to have uncontrolled and/or untreated significant hypertension at Screening and antihypertensive treatment is initiated, assessment for study eligibility should be deferred until BP and antihypertensive medication have been stable for at least 1 month. For participants with previously diagnosed hypertension, antihypertensive medications must be stable for at least 1 month before Screening.
  43. Any macular findings on clinical examination or imaging suggestive of: moderate or advanced dry macular degeneration, geographic atrophy, moderate or advanced myopic degeneration, wet macular degeneration, pattern dystrophy or other pigmentary maculopathy, moderate or severe diabetic or hypertensive retinopathy, recent retinal vascular occlusion, macular hole or advanced epiretinal membrane with associated macular oedema, retinal dystrophy, toxic retinal maculopathy, chronic central serous retinopathy, presence of significant subretinal or intraretinal fluid (OCT finding), presence of vitelliform or vitelliform-like macular changes (OCT and clinical finding), severe maculopathy not otherwise specified.
  44. Morning cortisol \<3 μg/dL.
  45. Adrenocorticotropic hormone (ACTH) \<10 pg/mL.
  46. US/Canada only: Morning cortisol ≥3 μg/dL and \<10 μg/dL and peak cortisol (by ACTH stimulation [250 μg, IM] test) \<18 μg/dL at both 30 min and 60 min post stimulation.
  47. Current hyperkalaemia and/or hyponatremia.
  48. Contraindication to MRI.
  49. Largely or wholly incapacitated (e.g., bedridden or confined to a wheelchair, permitting little or no self-care).
  50. Major surgery or anticipated surgery during the study.
  51. Currently hospitalised or any planned hospitalizations during the study.
  52. Plan for total knee reconstruction in affected knee(s) during the study.
  53. Knee surgery or trauma to the index knee within 1 year before Day 1.
  54. A history of drug or alcohol abuse and/or dependence within the 12 months before Screening that, in the opinion of the Investigator, may affect participant ability to comply with study requirements.
  55. An employee of the Sponsor, clinical research organisation(s), or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
466 participants (estimated)

Study arms

  • Active comparator
    PPS

    Pentosan polysulfate sodium 2mg/kg twice weekly for 6 weeks

    Drug: Pentosan Polysulfate Sodium twice weekly

  • Placebo comparator
    Placebo

    Placebo (Sodium Chloride Injection, 0.9%) twice weekly for 6 weeks

    Drug: Placebo

Interventions

  • DrugPentosan Polysulfate Sodium twice weekly

    Subcutaneous injection, 2 mg/kg twice weekly for 6 weeks

  • DrugPlacebo

    Placebo, subcutaneous injection, twice weekly for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline at Day 112 in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.

    The NRS is an 11-point unidimensional scale for self-report of pain. The participant selects a whole number (0-10) that best reflects the intensity of their pain. The anchors are 0=no pain and 10=extreme pain/worst possible pain. It is often categorised into no pain=0, mild pain=1-3, moderate pain=4-6, severe pain=7-10. Participants will be asked to consider their average pain over the last 24 hours.

    Time frame: Baseline, Daily to Day 112

Secondary outcomes

  1. Change from baseline in function as assessed by the average functional subscale score of the WOMAC NRS 3.1 Index

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  2. Change from baseline in knee pain as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  3. Change from baseline in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.

    The NRS is an 11-point unidimensional scale for self-report of pain. The participant selects a whole number (0-10) that best reflects the intensity of their pain. The anchors are 0=no pain and 10=extreme pain/worst possible pain. It is often categorised into no pain=0, mild pain=1-3, moderate pain=4-6, severe pain=7-10. Participants will be asked to consider their average pain over the last 24 hours.

    Time frame: Measured at 21 timepoints from Screening to Day 404.

  4. Change from baseline in Patient Global Impression of Change (PGIC)

    The PGIC is a self-administered question that rates participants' overall improvement in chronic pain since beginning treatment from 1 "no change (or condition has worsened)" to 7 "a great deal better" in response to the question "Since beginning treatment, how would you describe the change (if any) in activity, limitation, symptoms, emotions, and overall QoL related to your arthritis".

    Time frame: Measured at 10 timepoints from Days 39 to 404.

  5. Change from baseline in knee stiffness as assessed by the average stiffness subscale score of the WOMAC NRS 3.1 Index

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  6. Change from baseline overall as assessed by the overall score of the WOMAC NRS 3.1 Index

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  7. Proportion of participants with ≥30% and ≥50% pain reduction from baseline as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index.

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  8. Proportion of participants with ≥30% and ≥50% improvement in function from baseline as assessed by the average pain subscale score of the WOMAC NRS 3.1 Index.

    The WOMAC NRS 3.1 Index is a validated, self-administered, health status questionnaire that assesses pain, stiffness, and function in patients with hip or knee OA (Bellamy et al., 1988). The WOMAC NRS 3.1 Index consists of 24 questions and produces 3 subscale scores for pain (5 questions), stiffness (2 questions), and function (17 questions) and a total score that summarises overall disability. Each question is scored from 0 to 10 using a standardised 11-point NRS. Each subscale score and the total score will be averaged to provide subscale and total scores between 0 and 10. Participants are to consider their last 4 hours when answering the questions.

    Time frame: Measured at 20 timepoints from Day 1 to 404.

  9. Number of days of rescue medication used

    In case of inadequate pain relief, either acetaminophen/paracetamol up to 3000 mg per day or topical analgesics, up to 4 days in a week may be taken as rescue medication between day 1 and Day 404. Participants will record all use of rescue and other pain medications/therapies in their electronic diary.

    Time frame: Recorded from Day 1 to 404

  10. Change from baseline in QoL as assessed by EQ-5D-5L.

    The EQ-5D-5L questionnaire is a self-assessed, health related, QoL questionnaire consisting of the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises of five dimensions, where each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions.

    Time frame: Measured at 13 timepoints from Days 1 to 404

  11. Change from baseline in cartilage volume and thickness on Magnetic Resonance Imaging (MRI).

    Gadolinium MRI images will be taken to measure changes in cartilage volume and thickness.

    Time frame: Measured at Days 1, 168 and 404.

  12. Change from baseline in joint synovitis/effusion volume on Magnetic Resonance Imaging (MRI).

    Gadolinium MRI images will be taken to measure changes in joint synovitis/effusion volume,.

    Time frame: Measured at Days 1, 168 and 404.

  13. Change from baseline in subchondral BML area and volume on Magnetic Resonance Imaging (MRI).

    Gadolinium MRI images will be taken to measure changes in subchondral BML area and volume,.

    Time frame: Measured at Days 1, 168 and 404.

  14. Change from baseline in bone shape/osteophytes on Magnetic Resonance Imaging (MRI).

    Gadolinium MRI images will be taken to measure changes in bone shape/osteophytes.

    Time frame: Measured at Days 1, 168 and 404.

  15. Change from baseline in joint space width on X-ray.

    X-ray for comparison of joint space width

    Time frame: Measured at Days 1 and 404.

  16. OMERACT-OARSI Responder Index response rate

    OMERACT-OARSI-Outcome Measures in Rheumatology-Osteoarthritis Research Society International. Participants are considered as an OMERACT-OARSI responder: if the change (improvement) from baseline to day of interest was greater than or equal to \>= 50 percent and \>= 2 units in either WOMAC pain sub-scale or physical function sub-scale score; if change (improvement) from baseline to week of interest was \>=20 percent and \>=1 unit in at least 2 of the following: 1) WOMAC pain sub-scale score, 2) WOMAC physical function sub-scale score, 3) Patient Global Impression of Change (PGIC).

    Time frame: Measured at 10 timepoints from Days 39 to 404.

  17. Change from baseline in Work Productivity and Activity Impairment (WPAI) questionnaire score

    The WPAI questionnaire (WPAI:OA-knee) is a validated self-administered questionnaire that assesses work impairment due to OA . The questionnaire gathers information on employment status, hours worked, hours missed due to OA, and hours missed for any other reasons.

    Time frame: Measured at 10 timepoints from Day 39 to 404.

  18. Incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in one or more of the following outcomes: death; life-threatening; requires in-patient hospitalization or prolongation of an existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; is an important medical event. Treatment-emergent means events occurring between the first dose of study drug and up to Day 404 that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: From enrollment to Day 404

  19. Incidence of treatment-emergent clinical abnormalities

    Treatment-emergent clinical laboratory abnormalities are abnormalities in laboratory results between the first dose of study drug and up to Day 404 that were absent before treatment or that worsened relative to pre-treatment state

    Time frame: From enrollment to Day 404

Other outcomes

  1. Exploratory: Characterize the AUC profile of single and multiple doses based on sparse blood sampling. (pharmacokinetic subset only)

    Blood samples for assay of plasma PPS concentration will be obtained from a subset of patients before dosing and 2, 4, and 6 hours after dosing on study Days 1, 15 and 39. On other days, a pre-dose sample will be collected. Samples will be assayed using a sensitive, validated bioanalytical method. Plasma concentrations of PPS will be tabulated by time and participant and inspected for relationship to dose during titration and stable treatment phases.

    Time frame: Days 1, 15 and 39 - pre-dose and 2, 4, and 6 hours. Pre-dose on day 4, 8, 11, 18, 22, 25, 29, 32, 36 and 39

  2. Exporatory: Number of participants with an Anti-Drug-Antibody (ADA) response after treatment and correlation with clinical events.

    Human serum ADA samples will be analyzed for the presence or absence of anti-drug-antibodies by using a semi-quantitative enzyme linked immunosorbent assay (ELISA).

    Time frame: Baseline, Days 11, 25, 39, 56 and 84.

  3. Exploratory: Change from baseline in serum biomarkers, including but not limited to, COMP, aggrecan ARGS, CRTAC-1, PRO-C2 PIIBNP, NTx-Ⅰ, and HA.

    ARGS-(aggrecan) alanine-arginine-glycine-serine; COMP-cartilage oligomeric matrix protein; CRTAC-1-cartilage acidic protein-1; HA-hyaluronic acid; NTx-1-N-terminal telopeptide of type I collagen; PIIBNP-N-terminal propeptide of type II collagen; PRO-C2-type II collagen C-terminal propeptide.

    Time frame: Measured at 11 timepoints from Day 4 to 168.

  4. Exploratory: Change from baseline of cartilage volume and thickness and whether these correlate with clinical pain outcomes.

    The correlation co-efficient of changes in cartilage volume and thickness as measured on MRI and pain clinical outcomes.

    Time frame: Screening, Day 168 and 404

  5. Exploratory: Change from baseline of subchondral BMLs, and whether these correlate with clinical pain outcomes.

    The correlation co-efficient of changes in subchondral BMLs as measured on MRI and pain clinical outcomes.

    Time frame: Screening , Day 168 and 404

  6. Exploratory: Change from baseline of bone shape and whether these correlate with clinical pain outcomes.

    • The correlation co-efficient of changes in bone shape changes as measured on MRI and pain clinical outcomes

    Time frame: Screening , Day 168 and 404

  7. Exploratory: Change from baseline of joint space width and whether these correlate with clinical pain outcomes.

    The correlation co-efficient between changes in joint space width as measured on X-Ray and clinical pain outcomes.

    Time frame: Screening and 404

07

Study locations

57 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 26 months is above that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Apr 8, 2025
StartActual
May 29, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06917404
Lead sponsor
Paradigm Biopharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
May 29, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Chief Medical Officer, Medical
study director · Paradigm Biopharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion